Michael Ackermann


Michael is a co-founder and CEO of Presidio Medical. Michael also serves as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST) and Chairman of Tarsus Pharmaceuticals, Inc. He was previously Vice President, Neurostimulation for Allergan, plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan. He received a B.E. degree in biomedical engineering from Vanderbilt University, M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University, is a graduate of the Stanford University Biodesign Fellowship and Vision Research Fellowship at Stanford University. He has numerous patents and peer-reviewed publications.


Kenneth Wu

PhD, President & CTO

Kenneth is a co-founder and President & CTO of Presidio Medical. He was previously COO of Siris Medical, Inc an AI platform for enhancing radiation oncology treatment planning and outcomes. Prior to that, he was an R&D Program Manager at Spiracur Inc., a company focused on wound healing therapies, moving multiple products through early development to commercial release including FDA clearance and manufacturing implementation. Spiracur’s technology was acquired by Acelity L.P. He received his B.S.E. degree in mechanical and aerospace engineering from Princeton University, M.S. and Ph.D. degrees in mechanical engineering from Stanford University and is a graduate of the Stanford University Biodesign Fellowship.


Ben Tsai

Ben is a partner at Invus Opportunities, a New York based investment firm that currently manages over $1.5 billion of capital. Ben joined Invus Opportunities in 2008 when the firm spun off from sister firm The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Ben leads investments by Invus Opportunities in growing private companies and works in close partnership with market-leading management teams and investors to create lasting value. Ben has served on the Board of Directors of numerous companies, both in the healthcare sector as well as in other industries. Prior to joining Invus Opportunities, Ben was a management consultant at the Monitor Group. Ben received a B.S. in business administration from the University of Southern California and an M.B.A. from Harvard Business School.


Juan-Pablo Mas

Juan-Pablo is a partner at Action Potential Venture Capital based in Palo Alto, CA, and invests in start-ups that are pioneering bioelectronic medicines. He is a Board member of various companies developing therapies that leverage “electricity as medicine,” a promising alternative to traditional drug therapies. He was previously a medical device investor at Lightstone Ventures and Morgenthaler Ventures. Prior to investing, Juan-Pablo led efforts across R&D and Strategy in Medtronic’s CardioVascular Division, and subsequently served on the CV Global Brand Strategy team at Eli Lilly. Juan-Pablo earned an MBA from Stanford Graduate School of Business, an M.S. in Electrical Engineering from Stanford, and a B.S. in Electrical Engineering from the University of Massachusetts. He serves on the Oversight Committee for Stanford’s Neuroscience Institute (Wu Tsai), the Advisory Board for UCSF’s Rosenman Institute, and is a founding Board Member of LatinxVC.


Michael Onuscheck

Michael is President, Global Business & Innovation at Alcon. Previously, Michael led Alcon’s Surgical business as President & General Manager. Michael joined Alcon in February 2015 from Boston Scientific. Michael held the position of President of Boston Scientific EMEA. He previously served as Senior Vice President and President of Boston Scientific’s Neuromodulation Division. Prior to the Boston Scientific acquisition of Advanced Bionics (BSC Neuromodulation), Michael held a variety of marketing and sales management positions at Medtronic Sofamor Danek. He also held various sales and management positions for Pfizer. Michael earned his degree in Business Administration and Psychology from Washington and Jefferson College in Washington, Pennsylvania.